Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Fellowship - Priority Announcement: Hepatology

University of Toronto

$45,000.00

T Cell Immunity in HIV-1/HCV Coinfection

FY 2011-12

Summary
Hepatitis C virus (HCV) infects close to 300 million persons worldwide, is a major cause of end-stage liver disease and is the primary reason for liver transplantation in North America. Human immunodeficiency virus type 1 (HIV-1) infects close to 40 million individuals worldwide. In those coinfected with HIV-1 and HCV, despite the availability of antiretroviral treatment for HIV-1 infection, end-stage liver disease due to HCV is an important cause of morbidity and mortality. Defining the causes of HCV disease progression in the setting of HIV-1 coinfection are necessary to improve therapeutic options and slow the development of liver disease, given that the current therapy for HCV disease in HIV-1 infected individuals is often ineffective. This proposal will examine why HIV-1 worsens HCV disease. Firstly, we will study whether HIV-1 infection can influence the immune response of co-infected persons such that it is less effective at containing HCV. We will then investigate whether coinfection with HIV-1 leads immune cells to secrete factors which may inhibit the antiviral activities of particular immune cells that are vital to the anti-HCV immune response. We will further study whether HIV-1/HCV coinfection leads to an accumulation or poor regulation of immune cells that secrete inflammatory factors, in the liver, thereby leading to liver inflammation and damage. The proposed research could uncover the causes of immune dysfunction observed in HIV-1/HCV infected persons may lead and improvement in the health of these individuals through the development of immune-based therapies to lessen the HCV burden and slow the development of serious liver disease and related mortality.
Program
Fellowship - Priority Announcement: Hepatology
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
243247
Name
MacParland Sonya
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
The Canadian Association for the Study of Liver
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
T Cell Immunity in HIV-1/HCV Coinfection
Programtype2
Fellowship Programs
Orgnameinp2
University of Toronto
Cihramount2
$45,000
Cihrequipment2
$0
Programname2
Fellowship - Priority Announcement: Hepatology
Keyworddelim
Cd4+ T Cells; Cytokines; Hcv; Hiv-1; Hiv/Hcv Coinfection; Immunology; Liver Disease; Liver Fibrosis; T Cell Exhaustion; T Cell Responses
Abstract
Hepatitis C virus (HCV) infects close to 300 million persons worldwide, is a major cause of end-stage liver disease and is the primary reason for liver transplantation in North America. Human immunodeficiency virus type 1 (HIV-1) infects close to 40 million individuals worldwide. In those coinfected with HIV-1 and HCV, despite the availability of antiretroviral treatment for HIV-1 infection, end-stage liver disease due to HCV is an important cause of morbidity and mortality. Defining the causes of HCV disease progression in the setting of HIV-1 coinfection are necessary to improve therapeutic options and slow the development of liver disease, given that the current therapy for HCV disease in HIV-1 infected individuals is often ineffective. This proposal will examine why HIV-1 worsens HCV disease. Firstly, we will study whether HIV-1 infection can influence the immune response of co-infected persons such that it is less effective at containing HCV. We will then investigate whether coinfection with HIV-1 leads immune cells to secrete factors which may inhibit the antiviral activities of particular immune cells that are vital to the anti-HCV immune response. We will further study whether HIV-1/HCV coinfection leads to an accumulation or poor regulation of immune cells that secrete inflammatory factors, in the liver, thereby leading to liver inflammation and damage. The proposed research could uncover the causes of immune dysfunction observed in HIV-1/HCV infected persons may lead and improvement in the health of these individuals through the development of immune-based therapies to lessen the HCV burden and slow the development of serious liver disease and related mortality.
Competitiondate
201110
Approvedterm2
2 yrs 0 mth
Pinamesdelim
MacParland, Sonya
Approvedterm
2 ans 0 mois
Cihrcontribution2
Patient Oriented Research~ $45,000~ $0~